Neutralizing antibodies for treating hepatitis E in high-risk patients identified
Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...
Hepatitis C Testing Market to Reach $2.6 billion, Globally, by 2035 at 4.9% CAGR: Allied Market Research
Expansion of government screening programs, rise in prevalence of hepatitis c & need for its early detection, and advancements in diagnostic technologies drive the growth of the global hepatitis C ...
Medscape3d
Case Report: Passive Transfer of Hepatitis B Antibodies From Intravenous Immunoglobulin
With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...
PharmiWeb8d
Polyclonal Antibody Market Poised for Growth, Expected to Hit USD2.0 Billion by 2034 at 5.5% CAGR- TMR
The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...
Informationsdienst Wissenschaft9d
Better fight against hepatitis E
Neutralising antibodies can prevent severe courses Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with weakened immune system or existing ...
Clinical Advisor4d
Hepatitis C Rates in HIV More Than Doubled for Some Risk Groups From 1995 to 2023
Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.
PipelineReview.com8d
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...